Expert Financial Analysis and Reporting

Company Commentary (23)

Company Reports (522)

Investment Theses (5)

LinkedIn (236)

Market Commentary (2)

Smith On Stocks Blog (181)

.Delay in Quick Shot Testosterone Clinical Trials (1)

2016 Analysts Day (1)

2017 Results (1)

2018 (1)

2018 Northwest Biotherapeutics presentation at ASCO (1)

2019 (1)

2021 and 2022 (1)

4-Antibody (2)

7th Annual Phacilitate Immunotherapy Forum (1)

A.P. Pharma Inc. (12)

A.P. Pharma. APF530 (4)

AB Generic to EpiPen (1)

AB generic to EpiPen approval (1)

AB rated generic to Byetta (3)

AB Rated Generic to EpiPen (12)

AB rated generic to EpiPen launch (1)

AB Rated Generic to Forteo (3)

AB rated generic to Imitrex (3)

AB Rated version of EpiPen (1)

AB rated version of sumatriptan (1)

Achillion Pharmaceuticals (3)

ACTC (1)

Adam Feuerstein (7)

Adam Feuerstein blog on Portola (1)

Addressable market for Palforzia (1)

adenovirus (1)

Adolor Corporation (8)

adult neural stem cells in ALS (1)

Advanced Cell Technology (1)

Advanced Cell Techology. ACTC (1)

Advaxis (3)

AdVise trial of brincidofovir (3)

ADXS (3)

Aerosurf (19)

Aerosurf Phase 2 trials (1)

Aerosurf Phase 2b proof of concept trial (1)

Aerosurf Phase 2b Trial (1)

Afectair (1)

AGEN (26)

Agenus (31)

Agenus and InCytre (1)

Agenus checkpoint modulators (1)

Agenus collaboration with Incyte (1)

Agenus development of checkpoint modulators (1)

Agenus development of neonantigen cancer vaccines (1)

Agenus Royalty deal with Oberlan Capital (1)

Aimmune (1)

Aimmune Therapeutics (2)

AIMT (1)

AIS (1)

Alexion (1)

ALIM (9)

Alimera (11)

Alimera 2017 second quarter results (1)

Alimera Sciences (2)

Alimera third quarter results (1)

Alkermes (1)

ALKM (1)

Aloxi (1)

ALPMY (1)

ALS (9)

Alternating Tangential Flow Filtration (1)

ALXN (1)

AMAG (9)

AMAG divests Cord Blood Registry (1)

AMAG Pharmaceuticals (5)

AMAG Pharmaceuticsals (1)

Amgen (6)

Amgen and omecamtiv mecarbil (1)

Amgen's view of omecamtiv (2)

AMGN (2)

AminoMatrix (1)

AmniMatrix (1)

Amnioexcel (4)

Amniomatrix (2)

Amylin acquisition (1)

amyotrophic lateral sclerosis (1)

Anadys Pharmaceuticals (7)

AncexXa PDUFA extended to May 4 (1)

andexamet (1)

AndexXa (2)

AndexXa (andexamet alpha) (1)

Andexxa 1Q 2019 sales (1)

AndexXa addressable market (1)

AndexXa approval (1)

AndexXa approval on May 4 (1)

Andexxa launch (3)

Andexxa PDUFA date and launch (1)

Andexxa sequential sales drop in 4Q (1)

Antares (9)

Antares comments on Type A meeting with FDA (1)

Antares Pharma Inc. (77)

Antares Pharmaceuticals (1)

Antares Presentation at Jefferies (1)

Antares response to Complete Response Letter (1)

Antares Sales and Earnings Model (1)

Antares Sales and Earnings Projections through 2022 (1)

APF530 (1)

APPA (2)

APPA.OB (1)

approval of AB rated generic to EpiPen (1)

Approval of AndexXa (1)

AR 101 and peanut allergy (1)

Aradigm (1)

ARDM (1)

Arena Pharmaceuticals (3)

ARGS (1)

Argus Therapeutics (1)

Astellas (1)

ATF (1)

ATF Cell filtration systems (1)

Athersys (3)

ATHX (2)

atomic-ahf (2)

ATRS (49)

Auriclosene (2)

Axi-Cel (1)

Axi-Cel (axicabtagene ciloleucel) (2)

Axi-Cel product launch (1)

AzaSite (1)

AzaSite Plus (2)

bacterial conjunctivitis (1)

Bacterial Resistance (1)

Battelle (1)

BENEFIT-ALS (7)

betrixaban (2)

betrixaban approval by FDA (1)

Bevyexxa approval (1)

bevyexxa manufacturing issue (1)

Bevyexxa US launch (1)

Bevyxxa (betrixaban) (1)

Bevyxxa launch (1)

Bevyxxa launch and manufactruing issues (1)

Bill Ackman of Pershing Square (1)

Bio CEO (1)

BioDelivery Sciences International (2)

Bioequivalence study for Makena (1)

Biotech Showcase (1)

biotechnology (1)

biotechnology market corrections (1)

biotechnology stock manipulation (1)

blepharitis (1)

BMS-986094 (1)

BMY (9)

borrowing cost for short sellers (1)

brincidofovir (4)

Brincidofovir in AdVise (1)

Bristol-Meyers (BMY) (2)

Bristol-Myers Squibb (28)

BromSite (2)

Cadence Pharmaceuticals (27)

CADX (10)

Caladrius (1)

Caladrius Biosciences (1)

cancer vaccine (1)

cancer vaccine trial failures (1)

cancer vaccines (1)

cancer vaccines for glioblastoma (1)

CAR_T products supported by Cryoport (1)

CAR-T (3)

CAR-T cells (3)

CAR-T Products (1)

CAR-T Therapy (2)

Catalyst Pharmaceutical Partners Inc. (2)

CBST (4)

CDX-011 (4)

CDX-1127 (4)

CDX-1135 (4)

Cede's role in illegal naked shorting (1)

ceftaroline (1)

ceftolozane/tazobactam (1)

Celator Pharmaceuticals (1)

Celgene (1)

Celldex (2)

Celldex Therapeutics (11)

Celldex Therapeutics Inc. (4)

cerdulatinib phase 2 trial in PTCL (1)

CHECKMATE-214 Interim Analysis (1)

checkpoint inhibitors (1)

checkpoint modulators (1)

checkpoint-027 clinical trial (1)

Checkpoint-568 clinical trial (1)

chemotherapy induced nausea and vomiting (1)

chimeric antigen receptor T-cells (1)

Chimerix (10)

Chinese ischemic stroke trial (1)

Citron Research (1)

CK-107 (4)

CK-107 in spinal muscular atrophy (2)

CK-2127107 (1)

CK-2127107 in copd (1)

CK2127107 (1)

CLBS (1)

CLDX (16)

Clinical data for Optune in glioblastoma (1)

Clinical hold on ROCKET trial (1)

clinical trial (1)

clinical trials (4)

CMRX (10)

Comparing Novocure and Northwest Biotherapeutics (1)

Comparison of three month data from JULIET trial with ZUMA-1 (1)

Corcept (1)

Cord Blood Registry (1)

CORT (1)

cosmic-hf (2)

COSMIC-HF trial in heart failure (1)

counterfeiting stocks (1)

CPXX (1)

CRL for ZS-9 (1)

cryogenically shipped live cells (1)

Cryoport (28)

Cryoport 1Q (1)

Cryoport 2Q sales (1)

Cryoport 4Q results (1)

Cryoport conference call (1)

Cryoport Equity offering June 20 (1)

Cryoport logistics services for CAR-T products (1)

Cryoport logistics support got CAR-T products (1)

Cryoport pre-announcement of 4Q (1)

Cryoport sales from launch of Kymriah and Yescarta (1)

Cryoport sales model through 2024 (1)

Cryoport second quarter 2017 results (1)

Cryoport Second Quarter Results (1)

Cryoport support of CAR-T saless (1)

Cryport and the Yescartsa launch (1)

CTL-019 (2)

CTL-019 (tisagenlecleucel-T) (2)

CTL-019 product launch (1)

Cubicin (3)

Cubist (6)

Cubist Pharmaceuticals (2)

CUR (31)

Curis Inc. (1)

CYDT (1)

CYRX (9)

cytk (59)

CytoDyn (1)

Cytokentics collaboration with Astellas (1)

Cytokientics (1)

Cytokinetics (63)

Cytoknetics (1)

Cytoknetics deal with Astellas (1)

cytomegalovirus (1)

cytomegalovirus infections (1)

daptomycin (2)

Data on 39 patients from phase 1 trial of DCVax Direct (1)

Davonex (1)

DazaSite (1)

dcvax direct (28)

DCVax Direct Phase 1 Trial at ASCO (1)

DCVax Direct Phase 1/2 trial (1)

DCVax-L (28)

DCVax-L and Right to Try law (2)

DCVax-L blinded phase 3 results (1)

DCVax-L data versus Optune (1)

DCVAX-L information arm (1)

DCVax-L interim results from phase 3 trial in glioblastoma (1)

DCVAX-L Phase 2 in colorectal cancer (1)

DCVax-L phase 3 in newly diagnosed glioblastoma (3)

DCVax-L Phase 3 screening halt (1)

DCVax-L phase 3 trial (1)

DCVax-L phase 3 trial in glioblastoma (1)

DCVax-L Phase 3 trial in newly diagnosed glioblastoma (2)

DCVax-L survival tail in newly diagnosed glioblastoma (1)

Deaths in ROCKET trial in r/r Adult ALl (1)

Dendreon Corporation (21)

dendritic cell cancer vaccines (4)

dendrtic cell cancer vaccines (1)

DERMA Phase III (2)

Derma Sciences (10)

Detailed earning forecast for Antares (1)

Detailed sales and earnings forecast model for Portola through 2021 (1)

DexaSite (2)

diabetic macular edema (2)

Dificid (1)

Discovery Laboratories Inc (30)

Discovery Laboratories Inc. (1)

Discovery Laboratries (1)

DME (1)

DNDN (2)

Dr. Eva Feldman (1)

Dr. Keyoumers Ashkan speaks on DCVax-L (1)

Dr. Linda Liau Speaks on DCVax-L (2)

DRRX (1)

drug price increases (1)

DSC-127 (3)

DSCI (10)

DSCO (22)

Durect (1)

Dyax Corp. (1)

Eamonn Hobbs (3)

EAMS (1)

Early Access to Medicines Scheme (1)

Ebola treatments. Brincidofovir use against Ebola (1)

edaravone approval in ALS (1)

Eliquis (1)

engineered autologous T cells (1)

Epi-Pen (1)

EpiPen (4)

European Society of Cardiology (1)

Expanded collaboration with Astellas (1)

Failure of phase 2b trial of Aerosurf (1)

failure to deliver stocjk (1)

FDA (2)

FDA accepts NDA resubmission as complete (1)

FDA action on Xyosted regulatory review (2)

FDA AdCom action on Lipocine's Tlando (1)

FDA Oncologics Drug Advisory Committee Meeting on Novaris' tisgenlecleucel (1)

Feraheme (1)

fidoxomicin (1)

Financing (1)

FORTITUDE-ALS Trial Results (1)

Fusilev (2)

GAIN Act (1)

Galderma (1)

GE decides to manufacture Protin A (1)

German hospital exemption early access (3)

GERN (2)

Geron (2)

Gilead (2)

Glaxo (3)

glembatumumab (4)

glembutumamab (1)

glioblastoma (5)

glioblastoma multiforme (4)

granisetron (2)

GSK (2)

GSK malaria vaccine (1)

hematopoiectic cell transplants (1)

Heron Therapeutics (13)

HRTX (1)

HTC (1)

hyperkalemia (1)

ICT-107 (7)

illegal naked shorting (12)

illegal naked shorting by hedge funds (1)

illegal naked shoting (1)

Iluvien (8)

Iluvien in diabetic macular edema (1)

Iluvien sales trends (1)

Immuno-oncology (2)

Immuno-oncology therapies (1)

ImmunoCelluar Therapeutics (1)

ImmunoCellular (4)

ImmunoCellular Therapeutics LTD (17)

Impact on Antares of Makena SC approval (1)

IMUC (16)

IMUC. Senesco (1)

In-depth report on AMAG (1)

Inc. (24)

Incivo (1)

Industry news (1)

Inhibitex (1)

INO (1)

Inovio (2)

InSite Vision (10)

INSV (3)

INSV.OB (1)

Intermezzo (2)

Investment Conferences (1)

JCAR-015 (1)

JCAR-015 clinical hold in Rocket trial (1)

JCAR-017 (1)

JCAR015 (1)

JNJ (1)

Johnson & Johnson (13)

JP Morgan (1)

JULIET trial (1)

July 12 AdCom Meeting for CTL-019 (1)

June 24th PDUFA date for betrixaban (1)

JUNO (8)

Juno and Kite CAR-T development programs (1)

Juno Celgene CAR-T Deal (1)

Juno Therapeutics (4)

KaloBios (2)

KBIO (2)

Kefzara (1)

Keytruda (3)

KITE (19)

Kite October 18 (1)

Kite Pharma (11)

KIte Pharma in CAR-T (1)

Kite Pharmaceuticals (1)

KL-4 (2)

KTE-C19 (6)

KTE-C19 in r/r DLBCL (1)

Kymriah (1)

Kymriah launch (1)

Kymriah sales projections (1)

kyperkalemia (1)

launch of AB rated generic to EpiPen (1)

Launch of CAR-T products CTL-019 and Axi-Cel (1)

launch of subcu dosage form of Makena (1)

Launcj of Makena subcutaneous auto-injector (1)

lending stock to short sellers (1)

Lifting partial hold on phase 3 trial of DCVax-L (1)

Linda Powers (1)

linezolid (1)

Lou Gehrig's disease (3)

LTD (1)

lucinactant (1)

MAGE A-3 (2)

MAGE-A3 (1)

major depressive disorder (1)

Makena (4)

Makena AdCom Meeting (2)

Makena Auto-Injector (2)

Makena launch and market opportunity (1)

Makena subcu dosage form launch (1)

Makena subcu launch (1)

Malaria (1)

Mallinckrodt (1)

managed care (1)

manufactruing issues with Bevyxxa (1)

manufacturing cost of DCVax-L (1)

Manuscript on blinded data from phase 3 trial of DCVax-L (1)

MAP Pharmaceuticals Inc. (4)

market and stock manipulation (1)

Marnix Boscg comments at 209 ASCO (1)

Martin Shkreli (1)

Martin Shrkeli arrest (1)

Medac (2)

Medac Pharma (1)

Medidur (1)

Medihoney (6)

Medivation Inc. (1)

MELA Sciences (1)

Merck (1)

mestastic breast cancer (1)

methotrexate (3)

methylated MGMT (1)

MNK (1)

MRK (1)

MYL (1)

Mylan (1)

naked shorting (1)

NBIX (1)

NBS (1)

NBY (6)

nCPAP and Aerosurf (1)

Neil Woodford (1)

Neil Woodword (1)

NeoStem (1)

neural stem cells (1)

Neuralstem and Stem Cell patent litigation (1)

Neuralstem, Inc. (34)

Neurastem (1)

Neurocrine (1)

non-opioid analgesics (1)

Northest Biotherapeutics (2)

Northwest Bioteheraepeutics. NWBO. ICT-107. DCVax-l (1)

Northwest Biotheraepeutics (1)

Northwest Biotherapeutics Board of Directors (2)

Northwest Biotherapeutics Inc. (92)

Northwest Biotrherapeutics (1)

Nothwest Biotherpeutics (1)

NovaBay (8)

Novabay Pharmaceuticals (4)

Novartis (3)

Novocure (1)

NSI neural stem cells used to treat ALS (1)

NSI-189 (4)

NSI-189 in major depressive disorder (3)

NSI-566 (9)

NSI-566 neural stem cells (1)

NSI-566 neural stem cells in ALS (2)

NSI-566 stem cells (2)

NSI-566 stem cells in ALS (1)

NWBO (68)

NWBO. Northwest Biotherapeutics. ImmunoCellular (1)

NWBOD (1)

Ofirmev (8)

Ohr Pharmaceuticals (2)

OHRP (2)

Omecamtiv (5)

omecamtiv in congestive heart failure (2)

omecamtiv in GALACTIC-HF (1)

omecamtiv mecarbil (17)

omecamtiv mecarbil GALACTIC-HF trial (1)

Omecamtiv mecarbil results in COSMIC-HF (1)

omecamtiv mercarbil (2)

omecamtiv mercarbil in GALACTIC-HF (1)

omecsmtiv mecarbil in congestive heart failure (1)

OMED (1)

OncoMed Pharmaceuticals (1)

Onconova Therapeutics (1)

OncoSec Medical (1)

ondansetron (1)

Ondexxya EU conditional approval (1)

One Med Forum (1)

ONTX (1)

Opdivo (3)

Opdivo in first line non small cell lung cancer (1)

Opdivo misses endpoint in Checkpoint-26 (1)

Opdivo Yervoy combination (2)

OPUS (4)

OPUS Chromatography columns (2)

OPUS Disposable Chromatography Columns (1)

oral hepatitis C drugs (1)

Orencia (2)

Orexigen Therapeutics (7)

oritavancin (1)

Otrexuo (2)

otrexup (20)

Otrexup launch (2)

oxazolidinone (1)

Ozurdex (1)

Palforzia for desensitization of peanut allergy (1)

patiromer (4)

Paul Wotton (2)

PCT cell based manufacturing (1)

pending launch of Xyosted (1)

Pfizer Inc. (3)

Pharmasset (1)

Phase 1/2 Trial of DCVax Direct (1)

Phase 2 trial of NSI-566 neural stem celss (1)

Phase 2b trial of Aerosurf (1)

Phase 3 trial of DCVax-L in newly diagnosed glioblastoma (1)

phase II (1)

Portola (25)

Portola price targets (1)

potential contribution to Antares profits from Makena auto-injector (1)

Potential reasons for Xyosted CRL (1)

President Trump's remarks on right to try (1)

Prophage (4)

Prophage G-100 (2)

Prophage in glioblastoma (1)

Prophage therapeutic cancer vaccines (1)

Protein A (1)

Protein A ligand (1)

Provenge (2)

PSDV (9)

PSI-7977 (1)

pSivida (3)

pSivida Corp (7)

psoriasis (1)

PTLA (7)

Q3 Results (1)

QS 21 Stimulon vaccine adjuvant (1)

QS-21 Adjuvant (1)

QST (6)

QST testosterone replacement (1)

Quick Shot Testosterone (6)

Radicava approval in ALS (1)

Rapid progressors (1)

Rasuvo (2)

ReACT (1)

ReAct Trial (1)

reccomended stocks (1)

Refine Technology (1)

Regeneron's Kevzara could reduce mortality from COVID-19 (1)

REGN (1)

reldememtiv in ALS (1)

reldesemptiv in SMA (1)

reldesemtiv in SMA (1)

Relypsa (14)

Relypsa takeover (1)

Relypsa takeover rumors (1)

Repligen (18)

Repligen acquires Spectrum (1)

Repligen acquisition of Atoll (1)

respiratory distress syndrome (2)

Resubmission of AndexXa BLA (1)

Results from ZUMA-1 trial of KTE-C19 (1)

RGEN (13)

rheumatoid arthritis (2)

Richard Pearson (3)

Rigel (1)

Rigel Pharmaceuticals (1)

RIGL (2)

Rindopepimut (10)

Rintega (1)

Rintega (rindopepimut) (1)

Rintega failure in phase 3 ACT IV trial (1)

RLYP (11)

Royalty deal with Royalty Partners on Omecamtiv (1)

RTS (1)

RYLP (2)

S (1)

Sales projections for Xyosted in 2020 (1)

San Francisco (1)

Sangamo (1)

Sangamo BioSciences (2)

Sanofi (1)

Santarus Inc. (10)

Savient Pharmaceuticals (4)

Senesco (2)

Servier and omecamtiv mecarbil (1)

SGMO (1)

Shire plc (1)

Short selling (1)

Sivextro (1)

Skin Substitutes (1)

smithonstocks (1)

Smithonstocks Mailbox (1)

SmithOnStocks Top Stock Picks for 2017 (1)

SNTI (3)

SNY (1)

Spectrum Pharmaceuticals Inc. (3)

Statistical analysis plan for DCVax-L phase 3 trial (2)

STEM (1)

stem cell treatment of ALS (2)

Stem Cells (1)

StemCells (1)

Steven Hawking (1)

Stock manipulation (4)

stock manipulation by hedge funds (1)

stock manipulation scheme against Northwest Biotherapeutics (1)

stock manipultion (1)

stock performance (1)

Sub-cutaneous injection dosage form of Makena (1)

subcutaneous formulation of Makena (2)

Subcutaneous Makena launch (1)

subcutaneous methotrexate (1)

Sufaxin (1)

SUPPRESS trial of brincidofovir (3)

Surfactant (1)

Surfaxin (8)

Surfaxin LS (2)

Surfxin (1)

Surviival Tail of DCVax-L in Newly Diagnosed Glioblastome (1)

suspension of screening in DCVax-L phase 3 trial (1)

Suspension of screening in DCVax-L trial (1)

SUSTAIN and SURPASS trials of brincidofovir (1)

Syvextro (1)

talimogene laberparepvec (1)

Targacept (1)

TCC-EZ (6)

ted (1)

tedizolid (6)

Tedizolod (1)

Teflaro (1)

testosterone replacement market (1)

Tethadur (2)

teva (2)

Teva launches AB generic to Imitrex (1)

third quarter of 2017 (1)

tirasemetiv VITALITY-ALS trial (1)

tirasemtiv (24)

tirasemtiv in phase 3 VITALITY-ALS Trial (2)

tirasemtiv phase 3 in ALS (3)

tirasemtiv phase 3 trial (1)

tirasemtiv versus edaravone in ALD (1)

tirasmetiv (1)

Titan (1)

Total Contact Casting (1)

Tracking Xyosted Prescriptions (1)

Transcept Pharmaceuticals (14)

Treatment for COVID-19 (1)

Treatment pf hyperkalemia (2)

TRGT (1)

Trius CVR (1)

Trius Therapeutics (15)

TSPT (3)

TSRX (4)

TTPI (1)

tumor mutational burden (1)

UCBE (2)

Uncertainty about FDA approval of AndexXa (1)

unmehtylated MGMT (1)

unmethylated MGMT (1)

Valeant Pharmaceuticals (1)

Valtessa (1)

vancomycin (1)

varilumab (2)

varlilumab (3)

Veltassa (7)

Veltassa Launch (2)

Veltassa March 2016 results (1)

VGX-3100 (1)

ViroPharma Inc. (1)

VITALITY-ALS (3)

VITALITY-ALS trial fails (1)

Vivus Inc. (3)

VRX (1)

Windtree licensing deal with Lee's Pharmacetical (1)

Windtree Therapeutics (33)

WINT (4)

Woodford Financing (1)

wound dressing (1)

Xarelto (2)

Xyosted approval (1)

Xyosted CRL (2)

Xyosted launch (4)

Xyosted Launch Progress (1)

Xyosted prescription trends through September 20 (1)

Xyosted sales projections (1)

Yervoy (1)

Yescarta (1)

Yescarta launch (1)

Yescarta sales projections (1)

ZS Pharma (4)

ZS-9 (8)

ZSPH (4)

ZUMA-1 (2)

ZUMA-1 interim results with KTE-C19 (1)

ZUMA-1 results (1)

ZUMA-1 trial (1)

Zytiga (1)

Zyvox (2)